Hers vs Medvi

Choose hers if: You are female with multiple health needs beyond weight loss - particularly common combinations like obesity + PCOS-related hair loss, obesity + depression/anxiety, or obesity + hormonal skin issues benefiting from coordinated women-specific medical care. You value extensive women's health platform consolidating diverse treatments (weight loss, hair loss, mental health, skincare) through integrated provider network with female health expertise. You want the 7+ years of proven service behind you for treatment continuity for chronic management. You may utilize tirzepatide for superior weight loss efficacy versus semaglutide-only restriction. You appreciate multi-category scale and proven business viability despite higher costs ($199-349/month).

Choose Medvi if: You need exclusively weight loss medication at absolute lowest cost without other health services, with $197-247/month providing meaningful savings of $288-1,224 annually compared to hers. You have straightforward medical history unlikely to benefit from wide-ranging women's health expertise or multi-condition coordination. You can accept an emerging platform (<2 years of history) with little yet to show on longevity. You are satisfied with semaglutide-only access without need for tirzepatide option. You serve any gender (men, women, non-binary) as Medvi provides universal access versus hers female-only policy. You prioritize immediate cost minimization over multi-service integration and certainty.

Bottom line: hers and Medvi serve different patient needs - hers offers full-spectrum women's health integration ($199-349/month) with 7+ years behind it, multi-category coordination (weight loss + hair loss + mental health + skincare), female health expertise, dual GLP-1 formulary, serving female patients with multiple interconnected health concerns, while Medvi provides ultra-budget single-category weight loss ($197-247/month) with universal gender access, emerging platform status (<2 years), semaglutide-only restriction, and minimal services beyond medication for cost-conscious patients of any gender seeking exclusively lowest-price GLP-1 access. For women with multiple health needs, PCOS, depression, or other conditions benefiting from coordinated women-specific care, hers integrated platform delivers superior value through full expertise, treatment coordination, and medication options despite higher costs. For patients seeking exclusively budget-focused weight loss without gender-specialized services or multi-condition needs, Medvi's meaningful savings ($288-1,224 annually) may justify trade-offs in service scope and certainty - though emerging platform status presents greater long-term uncertainty compared to hers' established 7+ year track record.